Loading institutional data...
Loading institutional data...
Held by 192 of 5,944 reporting institutions (91th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -75%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~8.8% on $120M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $824.5M 100.0% | $837.6M 100.0% | $753.2M 100.0% | $678.4M 100.0% | $690.6M 100.0% | $557.1M 100.0% | $638.6M 100.0% | $851.1M 100.0% | $743.7M 100.0% | $771.4M 100.0% |
| Cost of Revenue | $247.9M 30.1% | $252.2M 30.1% | $236.2M 31.4% | $202.0M 29.8% | — | — | — | — | — | $145.2M 18.8% |
| Gross Profit | $576.6M 69.9% | $585.4M 69.9% | $517.0M 68.6% | $476.4M 70.2% | — | — | — | — | — | — |
| Research & Development | $106.8M 13.0% | $113.4M 13.5% | $88.7M 11.8% | $85.4M 12.6% | $81.9M 11.9% | $73.3M 13.2% | $77.2M 12.1% | $85.9M 10.1% | $70.8M 9.5% | $74.4M 9.6% |
| Selling, General & Admin | $256.8M 31.1% | $275.9M 32.9% | $572.9M 76.1% | $514.7M 75.9% | $537.8M 77.9% | $496.9M 89.2% | $507.3M 79.4% | $556.6M 65.4% | $435.0M 58.5% | $439.9M 57.0% |
| Total Operating Expenses | $963.8M 116.9% | $708.9M 84.6% | $774.4M 102.8% | $617.0M 90.9% | $881.1M 127.6% | $846.8M 152.0% | $870.3M 136.3% | $843.5M 99.1% | $621.8M 83.6% | $684.7M 88.8% |
| Operating Income | -$387.2M -47.0% | -$123.5M -14.7% | -$257.4M -34.2% | -$140.6M -20.7% | -$190.5M -27.6% | -$289.7M -52.0% | -$231.7M -36.3% | $7.6M 0.9% | $121.9M 16.4% | $44.0M 5.7% |
| Interest Expense | $10.5M 1.3% | $2.8M 0.3% | $2.9M 0.4% | $3.2M 0.5% | $6.6M 1.0% | $11.2M 2.0% | $10.8M 1.7% | $12.0M 1.4% | $3.2M 0.4% | $6.0M 0.8% |
| Interest & Investment Income | $1.8M 0.2% | $1.7M 0.2% | $2.5M 0.3% | $2.6M 0.4% | $700K 0.1% | $2.0M 0.4% | $3.0M 0.5% | $3.2M 0.4% | $1.8M 0.2% | $1.2M 0.2% |
| Other Income (Expense), net | -$7.9M -1.0% | $0 0.0% | -$4.8M -0.6% | $0 0.0% | $133.4M 19.3% | $6.1M 1.1% | $8.4M 1.3% | -$7.6M -0.9% | -$1.8M -0.2% | -$7.8M -1.0% |
| Pretax Income | -$395.1M -47.9% | -$123.5M -14.7% | -$262.2M -34.8% | -$140.6M -20.7% | -$57.1M -8.3% | -$283.6M -50.9% | -$223.3M -35.0% | $0 0.0% | $120.1M 16.1% | $36.2M 4.7% |
| Income Tax Expense | -$29.2M -3.5% | $3.8M 0.5% | $1.1M 0.1% | -$28.6M -4.2% | -$29.9M -4.3% | -$59.9M -10.8% | -$23.7M -3.7% | -$4.4M -0.5% | -$13.0M -1.7% | $19.0M 2.5% |
| Net Income | -$366.0M -44.4% | -$127.0M -15.2% | -$263.0M -34.9% | -$112.0M -16.5% | -$27.0M -3.9% | -$223.6M -40.1% | -$199.5M -31.2% | $4.6M 0.5% | $133.3M 17.9% | $17.4M 2.3% |
| Per Share | ||||||||||
| EPS (Basic) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $-2.69 | $0.06 | $1.92 | $0.25 |
| EPS (Diluted) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $-2.69 | $0.06 | $1.85 | $0.25 |
| Weighted Avg Shares (Basic) | 92.6M | 90.6M | 82.8M | 80.6M | 78.0M | 74.8M | 74.3M | 73.5M | 69.4M | 68.3M |
| Weighted Avg Shares (Diluted) | 92.6M | 90.6M | 82.8M | 80.6M | 78.0M | 74.8M | 74.3M | 76.0M | 72.0M | 68.8M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| MYGN | $387M | — | — | 0.5× | -1.6% | 69.9% | -44.4% | -99.4% | -75.0% | -0.3× | 192 |
Peers = companies sharing MYGN's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
Where each multiple sits in its own 15-yr range · 4th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 15-yr history.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | — | — | — | 29.8 | 31.4 | 30.1 | 30.1 |
| Gross Profit | — | — | — | — | 70.2 | 68.6 | 69.9 | 69.9 |
| R&D | 10.1 | 12.1 | 13.2 | 11.9 | 12.6 | 11.8 | 13.5 | 13.0 |
| SG&A | 65.4 | 79.4 | 89.2 | 77.9 | 75.9 | 76.1 | 32.9 | 31.1 |
| Operating Income | 0.9 | -36.3 | -52.0 | -27.6 | -20.7 | -34.2 | -14.7 | -47.0 |
| Income Tax | -0.5 | -3.7 | -10.8 | -4.3 | -4.2 | 0.1 | 0.5 | -3.5 |
| Net Income | 0.5 | -31.2 | -40.1 | -3.9 | -16.5 | -34.9 | -15.2 | -44.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on MYGN: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.